

Pediatric CIRB Meeting Agenda

July 10, 2025

I. Amendment Review

ALTE05N1, Umbrella Long-Term Follow-Up Protocol (Version Date 05/29/25)

II. Amendment Review

ANBL1531, A Phase 3 Study of ¹³¹I-Metaiodobenzylguanidine (¹³¹I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) (Version Date 06/05/25)

III. Continuing Review

AALL2131, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia," (Version Date 03/25/25)

IV. Continuing Review

AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (Version Date 09/17/24)

V. Continuing Review

ANBL2131, A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (Version Date 06/25/25)

VI. Continuing Review

APEC1621SC, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (Version Date)

VII. Continuing Review

APEC1621A, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions (Version Date 10/28/22)

VIII. Continuing Review

APEC1621B, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (Version Date 10/28/22)

IX. Continuing Review

APEC1621F, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)– Phase 2 Subprotocol of Ensartinib in Patients with Tumors harboring ALK or ROS1 Genomic Alterations (Version Date 06/11/24)

X. Continuing Review

APEC1621J, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations (Version Date 12/09/20)

XI. Continuing Review

APEC1621K, NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 subprotocol of AG-120 (ivosidenib) in Patients with Tumors harboring IDH1 mutations (Version Date 10/28/22)

XII. Continuing Review

APEC1621M, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations (Version Date 10/28/22)

XIII. Continuing Review

APEC1621N, NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations (Version Date 10/28/22)

XIV. Continuing Review

ARAR2221, Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) (Version Date 03/22/24)
